Celltrion And Teva Catch Up On Canadian Trastuzumab
Executive Summary
Celltrion and Teva have now received a Health Canada approval for their Herzuma trastuzumab biosimilar. However, notices of compliance have already been granted for rival biosimilars from Mylan and Pfizer.
You may also be interested in...
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks
By the end of June, Mylan expects to have launched in Canada the Ogivri trastuzumab 150mg and 440mg vials for which it has just received regulatory approval.
Teva Gets Canadian Rituximab Nod, But Barriers May Remain
Teva has obtained Health Canada clearance for biosimilar rituximab through an alliance with Celltrion. But the Israeli group is keeping quiet on launch plans as patent litigation continues.